Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 16;13(1):LMT66.
doi: 10.2217/lmt-2023-0014. eCollection 2024.

Inflammatory parameters in NSCLC with driver mutation

Mehmet Emin Buyukbayram  1 , Zekeriya Hannarici  2 , Ali Yilmaz  3 , Aykut Turhan  1 , Alperen Akansel Caglar  1 , Pınar Coban Esdur  1 , Mehmet Bilici  1 , Salim Basol Tekin  1
Affiliations

Inflammatory parameters in NSCLC with driver mutation

Mehmet Emin Buyukbayram et al. Lung Cancer Manag. .

Abstract

Aim: The tumor microenvironment of NSCLC with driver mutations, such as EGFR, ALK and ROS, is less inflammatory. Materials & methods: This retrospective study included 38 patients with NSCLC driver mutations. The relationship between clinical and inflammatory markers concerning progression-free survival and overall survival was analyzed based on Kaplan-Meier curves. Results: The mean age of the patients was 59.8 ± 11.9. Progression-free survival and overall survival were significantly longer in patients under 65 years of age and with low neutrophil-lymphocyte ratio, low systemic immune-inflammation index and high lymphocyte count (p < 0.05). Conclusion: Unlike tumor biology, peripheral inflammatory parameters, such as neutrophil-lymphocyte ratio, systemic immune-inflammation index and lymphocyte count may be associated with survival in NSCLC patients with driver mutations.

Keywords: driver mutation; inflammatory markers; non-small-cell lung cancer; survival.

Plain language summary

Lung cancer is the most common cancer worldwide and has a high mortality rate. Overall survival expectancy in metastatic NSCLC has increased from 11 months to 18 months. The detection of targeting mutations and the introduction of targeted treatments are the factors that increase overall survival. The contribution of immunotherapy to NSCLC is indisputable. The contribution of immunotherapy is low in NSCLC with driver mutation. We found that survival was associated with peripheral parameter indicators of inflammation despite the less inflamed tumor microenvironment. For immunotherapy to be effective in NSCLC, where there are not many treatment options, investigating different immune checkpoints or escape mechanisms and treatment planning for these will further improve survival.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Figures

Figure 1.
Figure 1.
Progression-free survival relationship of age and inflammatory parameters, Kaplan-Meier graphics. (A) Age, (B) NLR, (C) SII and (D) lymphocyte. NLR: Neutrophil–lymphocyte ratio; PFS: Progression-free survival; SII: Systemic immune inflammation index.
Figure 2.
Figure 2.
Overall survival relationship of age and inflammatory parameters, Kaplan-Meier graphics. (A) Age, (B) NLR, (C) SII and (D) lymphocyte. NLR: Neutrophil–lymphocyte ratio; OS: Overall survival; SII: Systemic immune inflammation index.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Liu Q, Huang Q, Yu Zet al. . Clinical characteristics of non-small-cell lung cancer patients with EGFR mutations and ALK & ROS1 fusions. Clin. Respir. J. 16(3), 216–225 (2022). - PMC - PubMed
    1. Solomon BJ, Mok T, Kim DWet al. . First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 371(23), 2167–2177 (2014). - PubMed
    1. Gao G, Ren S, Li Aet al. . Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from six phase III randomized controlled trials. Int. J. Cancer 131(5), E822–E829 (2012). - PubMed
    1. Yang JC, Wu YL, Schuler Met al. . Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 16(2), 141–151 (2015). - PubMed
    1. Mantovani A, Allavena P, Sica Aet al. . Cancer-related inflammation. Nature 454(7203), 436–444 (2008). - PubMed

    2. • Systemic inflammation causes worse prognosis in tumors.